Skip to main content

Kezar Life Sciences, Inc. (KZR)

NASDAQ: KZR · IEX Real-Time Price · USD
13.69 0.45 (3.40%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap672.82M
Revenue (ttm)n/a
Net Income (ttm)-51.36M
Shares Out49.15M
EPS (ttm)-1.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,137,817
Open12.84
Previous Close13.24
Day's Range12.99 - 13.77
52-Week Range4.61 - 14.35
Beta0.27
AnalystsStrong Buy
Price Target20.00 (+46.1%)
Earnings DateNov 4, 2021

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products includ...

IndustryBiotechnology
IPO DateJun 21, 2018
CEOJohn Fowler
Employees47
Stock ExchangeNASDAQ
Ticker SymbolKZR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for KZR stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 46.09% from the latest price.

Price Target
$20.00
(46.09% upside)
Analyst Consensus: Strong Buy

News

Why Kezar Life Sciences Stock Is Soaring Today

The company reported promising results from a phase 2 study.

1 week ago - The Motley Fool

Small-cap Biopharma Kezar Life Sciences Is Soaring, Here's Why

Kezar Life Sciences, Inc. (NASDAQ: KZR) shares are soaring Tuesday following a positive clinical readout. What Happened: California-based Kezar announced positive interim results from the Phase 2 portio...

1 week ago - Benzinga

Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

1 week ago - Business Wire

Kezar Life Sciences to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

2 weeks ago - Business Wire

Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.

ALEXANDRIA, Va. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.

2 weeks ago - Business Wire

Kezar Reports Third Quarter Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and ...

2 weeks ago - Business Wire

Kezar to Host Virtual Investor and Analyst Day on November 15, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

3 weeks ago - Business Wire

Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

1 month ago - Business Wire

Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

1 month ago - Business Wire

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

2 months ago - Business Wire

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyosi...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

3 months ago - Business Wire

Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and ...

3 months ago - Business Wire

Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

4 months ago - Business Wire

Kezar Life Sciences Announces Formation of Clinical Advisory Committee

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

5 months ago - Business Wire

Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

5 months ago - Business Wire

Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

5 months ago - Business Wire

Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

6 months ago - Business Wire

Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

6 months ago - Business Wire

Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

6 months ago - Business Wire

Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

6 months ago - Business Wire

Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncolo...

7 months ago - Business Wire

Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

8 months ago - Business Wire

Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and on...

9 months ago - Business Wire

Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and on...

9 months ago - Business Wire

Kezar Life Sciences: Targeting The Immunoproteasome To Treat Autoimmunity

Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhib...

9 months ago - Seeking Alpha